急性ST段抬高心肌梗死患者介入术后应用替格瑞洛强化抗血小板的效果分析

Effect of Tigrilol on Antiplatelet Therapy After Percutaneous Coronary Interventionin Patients with Acute ST Segment Elevation Myocardial Infarction

目的:探讨分析急性ST段抬高心肌梗死(STEMI)患者经皮冠状动脉介入术(PCI)后应用替格瑞洛强化抗血小板的效果。方法:选取2017年1月至2020年1月在笔者医院行PCI术治疗的100例STEMI患者作为研究对象,随机分为两组:观察组61例患者,给予替格瑞洛治疗;对照组39例患者,给予氯吡格雷治疗。结果:观察组的cTnI、IPA、并发症发生率低于对照组(P<0.05)。结论:和对STEMI患者PCI术后应用氯吡格雷相比,给予替格瑞诺具有更好的强化抗血小板的作用,其具有更高的安全性,值得推广使用。

Objective:To investigate the effect of tigrilol on antiplatelet after percutaneous coronary intervention(PCI)in patients with acute ST segment elevation myocardial infarction(STEMI).Methods:From January 2017 to January 2020,100 STEMI patients who were treated by PCI in our hospital were selected as object of study and randomly divided into two groups:61 patients in the observation group were treated with Ticagrelor,and 39 patients in the control group were treated with Clopidogrel.Results:The cTnI,IPA and incidence of complications in the observation group were lower than those in the control group(P<0.05).Conclusion:Compared with clopidogrel after PCI in STEMI patients,tigrenol has better antiplatelet effect,and it has higher safety,which is worthy of popularization and application.